The recent approval of subcutaneous nivolumab injection (Opdivo Qvantig) marks the next step in the evolution of cancer therapy—and one that promises new solutions for patients and cancer centers alike, according to an oncologist who spoke at the Association for […]
With Sub-Q Immunotherapy Coming, “Patient Preference Has to Be the Key” Read More »
In recent years, advances in clinical oncology have been offset by administrative burdens: more requirements from Medicare, more quality improvement tasks from payers, and especially more proof that a patient needs a drug or test before reimbursement happens. Speakers at
Bringing Data, Technology, and Advocacy to the Battle Read More »
For Amie J. Miller, MSN, APRN, AOCNP, ACHPN, CTTS, November always brings opportunity, and a little frustration. She was excited at how many attendees at the Association of Cancer Care Centers’ 51st Annual Meeting & Cancer Center Business Summit knew
Use of AI Lets Health System Find Lung Cancer at Early Stages Read More »
When it comes to cancer care in the United States, women are taking the lead: Nadine Barrett, PhD, MS, MPH, today concludes her yearlong term as president of the Association of Cancer Care Centers (ACCC), while Robin Zon, MD, FACP,
Lessons in Leadership, Challenges in Cancer Care Read More »
The need for more patients in clinical trials and especially more patients from diverse backgrounds hasn’t gone away, based on results from presented Wednesday evening at the opening of the Association of Cancer Care Centers (ACCC) 51st Annual Meeting &
ACCC Research Highlights Quest to Boost Trial Enrollment, Address Disparities Read More »
In January 2025, former FDA Commissioner Stephen Hahn, MD, and fellow panelists at the JP Morgan investors conference observed that pharma no longer follows a path of establishing a presence in one tumor type before moving to the next—today’s news
Planners of this week’s meeting of Association of Cancer Care Centers (ACCC) knew what they were doing when they selected Nick Webb, author of the book Chaotic Change: Embracing Chaos to Drive Innovation and Growth, to kick off the 51st
ACCC Meets in Capital’s Shadow Amid Changing Times Read More »
Studies involving prostate cancer presented during the recent American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) showed the importance of paying attention to each patient’s clinical features, along with diverse trial enrollment, according to an expert from City
What if your ability to receive the right treatment for prostate cancer came down to whether a doctor wrote down a math problem? It sounds far-fetched, but it’s not: The math calculation in question is called prostate-specific antigen doubling time
Getting More Doctors to Record a Life-Saving Prostate Cancer Calculation Read More »
Results from a phase 1 study presented Saturday showed that a 100 mg/day dose of casdatifan produced clinically meaningful responses in a third of patients previously treated for clear cell renal cell carcinoma (ccRCC).1 Toni K. Choueiri, MD | Image
